Noxafil (posaconazole) / Merck (MSD), Ligand - LARVOL DELTA

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (clinicaltrials.gov) - P2 | N=10 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed

Trial completion • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

The role of uridine diphosphate glucuronosyltransferase 1A4 polymorphisms on posaconazole exposure. (PubMed, Pharmacogenet Genomics) - "This study did not confirm the previously reported association between UGT1A4*3 and reduced posaconazole exposure and found no association with UGT1A4*2. Further studies are needed to determine the impact of homozygous UGT1A4 variants on posaconazole exposure."

Journal • Infectious Disease • UGT1A4

PERSISTING FEVER AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE REPORT OF A RARE INFECTION WITH LOMENTOSPORA PROLIFICANS (EBMT 2026) - "Cytoreductive therapy with hydroxyurea was initiated immediately after diagnosis, with no other prior antineoplastic treatment administered. Conditioning with fludarabine, thiotepa, and melphalan was started 7 months after the initial diagnosis...The patient received an HLA-identical unrelated male donor peripheral blood stem cell graft, with graft-versus-host disease prophylaxis comprising cyclosporine, mycophenolate mofetil, and anti-thymocyte globulin (ATG)...On day −3, the patient developed febrile neutropenia and broad-spectrum antibiotic treatment (piperacillin/tazobactam) was initiated. Recurrent fever on day +1 led to escalation to meropenem and a switch from fluconazole to posaconazole; blood cultures remained negative.Under these measures, the fever persisted...On day +11, increasing somnolence, pathological breathing pattern, and new oxygen requirement prompted sampling of peripheral and central blood cultures and empiric addition of linezolid and..."

Case report • Clinical • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • Febrile Neutropenia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Neutropenia • Respiratory Diseases • Septic Shock • Transplantation • ASXL1 • NRAS • RUNX1 • SETBP1 • SRSF2

POPULATION PHARMACOKINETICS OF CYCLOSPORINE A IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECEIVING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS (EBMT 2026) - "Although CsA PK has been extensively studied in traditional methotrexate-based protocols, data describing its disposition specifically within the context of PTCy are limited...Daily hematocrit (HCT) levels and concomitant administration of azole antifungals (fluconazole, voriconazole, posaconazole) were modeled as time-varying regressors to accurately capture the dynamic inhibition effect on clearance (CL)... This study characterizes CsA pharmacokinetics specifically in the PTCy setting, demonstrating that age, hematocrit levels and voriconazole co-administration are major determinants of exposure. Integrating this model into TDM software could facilitate precision dosing to improve clinical outcomes."

Clinical • PK/PD data • Post-transplantation • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation

OPEN WIDE: EXPLORING SALIVA AS A NON-INVASIVE TOOL FOR POSACONAZOLE LEVELS IN CHILDREN (EBMT 2026) - "This is the first prospective study assessing salivary detection of posaconazole in children. Our findings indicate that saliva sampling is unsuitable for posaconazole TDM in immunocompromised children. The minimal detection is possibly related to its high protein binding (>98%) similar to itraconazole and in contrast to voriconazole (~58%) and fluconazole (~10%), which have demonstrated reliable salivary penetration."

Clinical • Non-invasive • Infectious Disease • Mucositis • Stomatitis

POSACONAZOLE IN PAEDIATRICS: ARE WE HITTING THE MARK OR MISSING THE TARGET? (EBMT 2026) - "Posaconazole is effective in preventing and treating IFIs in children but requires higher than recommended doses to achieve therapeutic targets for treatment."

Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Pediatrics

ANTIFUNGAL PROPHYLAXIS PATTERNS AND INVASIVE FUNGAL INFECTIONS OUTCOMES IN PAEDIATRIC ALLOGENIC HCT: A MULTICENTRE COHORT STUDY (EBMT 2026) - "Choice of antifungal prophylaxis was classified as non–mould-active (fluconazole), mould-active (including micafungin, liposomal amphotericin B, voriconazole and posaconazole), or mixed (both non-mould active and mould active agents). Antifungal prophylaxis in paediatric allogenic HCT was strongly risk-adapted, with increased mould-active use in patients with prior history of IFI. IFIs occurred across all prophylaxis strategies, with all proven IFIs occurring in patients on fluconazole monotherapy. Most IFIs arose post-engraftment, highlighting the need for consistent, risk-based escalation to mould-active prophylaxis in immunosuppressed children."

Clinical • Infectious Disease • Pediatrics

Zoomlab™-Guided Co-crystal Engineering of Nilotinib for Improved Dissolution. (PubMed, Pharm Dev Technol) - "Validation with paracetamol and posaconazole datasets established 5 MPa0.5 as the optimal Δδv threshold. The optimized NH-PGCC capsule achieved 75% drug release in 15 minutes, significantly outperforming marketed formulations (Tasigna® and Nilotirel®) and reduction of crystallinity was less than 2% in 6 months, suggesting stability of co-crystal. This study successfully demonstrates the applicability of ZoomLab™ in coformer prediction and formulation development for solubility enhancement of poorly soluble drugs."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology

SMALL BOWEL PERFORATION AND DISSEMINATED HISTOPLASMOSIS IN A PATIENT WITH CROHN'S DISEASE: A CASE REPORT (CCCongress 2026) - "Her CD had previously been managed with oral budesonide continuously since diagnosis, infliximab and azathioprine for the past 8 years...She was started on amphotericin, posaconazole and began tapering steroids...Tissue diagnosis is essential, and infections such as histoplasmosis should be excluded prior to escalating immunosuppression. Although prior records confirming her CD were unavailable, chronic steroid use and anti-TNF therapy likely contributed to severe histoplasmosis that resulted in bowel perforation."

Case report • Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Bowel Disease

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial (ASH 2024) - "Background For fit patients (pts), combining kinase inhibitors (midostaurin, quizartinib) with intensive chemotherapy is standard of care for FLT3mutated AML...Clonal evolution of kinase-activating mutations, including FLT3-ITD is an important mechanism of treatment failure in pts with non-adverse (NON-ADV) cytogenetic risk AML receiving frontline therapy with azacitidine and venetoclax (AZA-VEN) (DiNardo and Tiong et al, Blood 2020). Incorporating kinase inhibitors (e.g. gilteritinib) into less-intensive VEN-based regimens in unfit, older pts has been challenging, with cumulative myelosuppression a dominant issue (Short et al, JCO 2024)...Posaconazole antifungal prophylaxis was permitted with dose adjustment of VEN to 50 mg daily and MIDO to 50 mg daily due to increased risk of cardiac toxicities in older populations...FLT3­-ITD MRD clearance was observed in 9/15 (60%) in the LVM arm and 1/4 (25%) in the LV arm. Conclusion In unfit, older pts ≥60 years with newly..."

Clinical • P2 data • Acute Myelogenous Leukemia • Constipation • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Neutropenia • FLT3

New advances and future prospect in antifungal therapy for invasive pulmonary aspergillosis (PubMed, Zhonghua Jie He He Hu Xi Za Zhi) - "New antifungal agents, such as isavuconazole, new formulations of posaconazole, liposomal amphotericin B, rezafungin, and eravacycline, exhibit distinct pharmacokinetic, pharmacodynamic, and safety profiles. Nanoparticle delivery systems and inhaled formulations have increased drug concentrations at the airway site while reducing systemic adverse effects. Future research will focus on new drug development targeting fungal protein targets, multi-target approaches, and immunomodulatory therapies."

Journal • Review • Pulmonary Disease • Respiratory Diseases

Pharmacovigilance insights: safety profiles of antifungal agents for invasive aspergillosis. (PubMed, Front Pharmacol) - "The safety profiles of FDA-approved antifungal agents, triazoles (Voriconazole, Posaconazole, Isavuconazole), polyenes (Amphotericin B), and echinocandins (Caspofungin), are not yet fully characterized in real-world settings. Amphotericin B and Caspofungin are associated with severe renal/hepatic toxicities and higher mortality, while Isavuconazole and Posaconazole may offer safer alternatives with delayed AE onset. Clinicians should prioritize drug-specific risks when tailoring treatment for IA patients."

Adverse events • Journal • Cholestasis • Hepatology • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Pulmonary Disease • Renal Disease • Respiratory Diseases

Treatment of pulmonary mucormycosis: current concepts. (PubMed, Expert Rev Anti Infect Ther) - "We emphasize aggressive host factor optimization (glycemic control, immunosuppression reduction) and outline the evidence-based antifungal strategy: liposomal amphotericin B (L-AMB) for induction, followed by oral maintenance (posaconazole or isavuconazole)...Combination antifungal therapy lacks definite evidence and should be reserved for severe or refractory cases. Future research priorities include prospective evaluation of treatment strategies, host-directed therapies, emerging antifungals (oral nanocrystal amphotericin, fosmanogepix, etc.), and systematic assessment of adjunctive modalities."

Journal • Review • Immunology • Infectious Disease • Nephrology • Renal Disease • Transplantation

Emerging Applications of Triazole Antifungal Drugs. (PubMed, Int J Mol Sci) - "The clinical utility of key antifungal agents, namely, posaconazole, isavuconazole, and voriconazole, is critically evaluated. We also examine the potential role of emerging agents such as opelconazole, which enables targeted pulmonary delivery and prolonged epithelial retention, representing a promising approach to IFI prevention. Drug-specific considerations, including pharmacokinetics, drug-drug interactions, toxicity profiles, and cost-effectiveness, are analyzed in the context of clinical decision-making. Finally, we emphasize the importance of tailoring antifungal strategies based on leukemia subtype, immunosuppressive status, and individual patient factors to optimize outcomes and support antifungal stewardship in hematologic malignancies."

Journal • Review • Acute Myelogenous Leukemia • Chemotherapy-Induced Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology

A Rare Case of Rhizomucor pusillus Infection in a 3-Year-Old Child with Acute Lymphoblastic Leukemia, Presenting with Lung and Brain Abscesses-Case Report. (PubMed, Infect Dis Rep) - "The present treatment protocol includes extensive and radical surgical debridement and systemic antifungal therapy with Liposomal Amphotericin B (L-AmB), Posaconazole, and Isavuconazole, either combined or as monotherapy. The patient underwent lung and brain surgery and is recovering well with no further complications. The two-year follow-up period shows no signs of recurrence of the disease."

Journal • Acute Lymphocytic Leukemia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Novel Coronavirus Disease • Oncology

Metagenomic Next-Generation Sequencing Enables Early Detection and Outcome Improvement in Perioperative Mucormycosis After Liver Transplantation: A Single-Center Experience. (PubMed, Int J Infect Dis) - "mNGS enables earlier detection of perioperative mucormycosis compared to conventional diagnostic methods and supports timely initiation of targeted therapy. Rapid mNGS-guided intervention may prevent progression to disseminated disease and improve prognosis in liver transplant recipients. Integration of mNGS into the diagnostic workflow is recommended for high-risk patients with unexplained pulmonary or cutaneous lesions."

Biomarker • Journal • Next-generation sequencing • Infectious Disease • Transplantation

Antifungal Susceptibility Testing Experience in the Management of Culture-Positive Mucormycosis: Observation from a Large Healthcare System. (PubMed, J Fungi (Basel)) - "Among the 36 who underwent AFST, posaconazole minimal inhibitory concentrations (MICs) were lower than isavuconazole (range 0.03 to 2 µg/mL versus 0.1 to 16 µg/mL, respectively). AFST led to a change in antifungal therapy in a minority of mucormycosis cases. Further studies to understand the epidemiological range of antifungal MICs and the effect of AFST-informed antifungal therapy are needed."

Journal • Hematological Disorders • Hematological Malignancies • Infectious Disease • Novel Coronavirus Disease • Oncology

Assessing voriconazole Etest as a surrogate marker for isavuconazole and posaconazole susceptibility in Aspergillus species (ESCMID Global 2026) - No abstract available

Misleading presentation of tuberculosis in a child with CGD revealing invasive aspergillosis: A molecularly confirmed case. (PubMed, IDCases) - "Molecular identification confirmed the isolates as A. fumigatus. According to the antifungal susceptibility testing, amphotericin B and posaconazole demonstrated strongest activity and the patient was successfully treated by liposomal amphotericin B (50 mg/day) and caspofungin (35 mg/day)."

Journal • Dermatology • Immunology • Infectious Disease • Pneumonia • Primary Immunodeficiency • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Identification of Druggable Binding Sites and Small Molecules as Modulators of TMC1 (ARO 2026) - "Unfortunately, ototoxic drugs such as aminoglycoside antibiotics and cisplatin exploit these channels to enter hair cells, often causing irreversible auditory and vestibular dysfunction...Docking results confirmed consistent binding of classical blockers such as benzamil and tubocurarine, as well as novel hits including cepharanthine, posaconazole, and lapatinib... This integrative approach combining pharmacophore modeling, molecular dynamics, docking, and in vitro validation establishes a versatile platform for discovering modulators of TMC1. The identification of multiple binding sites within the channel pore and validation of FDA-approved drugs as effective blockers highlights the translational potential of this work. By expanding the chemical space of candidate molecules, this study not only provides insights into the pharmacological modulation of TMC1 but also offers a rational framework for developing otoprotective therapies to counteract drug-induced hearing loss."

Otorhinolaryngology

Molecular Identification and Evaluation of Resistance to Antifungal Drugs in Candida Species Isolated From Diaper Rash of Neonates. (PubMed, Health Sci Rep) - "Nystatin, posaconazole, voriconazole, amphotericin B, ketoconazole, and clotrimazole showed high activity against all species (Minimum Inhibitory Concentration ≤ 0.125 µg/mL). The treatment of recurrent invasive candidiasis, needing repeated course of fluconazole or itraconazole, could be a risk factor for selecting resistant isolates. In addition, as the liposomal amphotericin B is no more commercialized in our country, a higher drug selection pressure for azoles may be expected in the future."

Journal • Candidiasis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Pediatrics

A Case of Persistent Candida Keyfr Bloodstream Infection in a Lung Transplant Recipient. (PubMed, Transplant Proc) - "Despite empiric antimicrobial coverage with vancomycin, meropenem, micafungin, and posaconazole, she continued to require high-dose vasopressors and remained unable to wean from veno-venous extracorporeal membrane oxygenation (ECMO)...Micafungin and posaconazole doses were increased, and intravenous (IV) liposomal amphotericin B was added...Micafungin and posaconazole were discontinued and IV voriconazole was started for eye penetration...To our knowledge, there are no documented cases in the literature of possible donor-derived C. kefyr leading to blood stream infection in the recipient. This case highlights the need for heightened clinical vigilance and prompt multidisciplinary management to mitigate the impact of post-transplant complications."

Journal • Cardiovascular • Genetic Disorders • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Retinal Disorders • Septic Shock • Solid Organ Transplantation • Transplantation • Uveitis

Restoring the pink of health: primary Rhodotorula mucilaginosa pneumonia in an immunocompetent host successfully treated with posaconazole (ESCMID Global 2026) - No abstract available

Infectious Disease • Pneumonia • Respiratory Diseases

Optimising Posaconazole Dosing in Children Through Population PK Modelling and Simulation (ESCMID Global 2026) - No abstract available

Clinical

Incidence and risk factors of breakthrough invasive fungal infection among patients with myeloid leukemia during posaconazole prophylaxis in King Chulalongkorn Memorial Hospital, Thailand (ESCMID Global 2026) - No abstract available

Clinical • Hematological Malignancies • Infectious Disease • Leukemia